03:31 PM EST - Knight Therapeutics Inc. : Has entered into an exclusive distribution agreement with Profounda Inc. to commercialize Impavido®(miltefosine), an oral treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States. Knight previously licensed the ex-U.S. global rights to Impavido® to Paladin Labs Inc. until February 2024. Knight Therapeutics Inc.
shares T.GUD are trading down $0.19 at $7.00.
